

EVALUESERVE

HFSA 2022 Pre-Conference Summary

SEPTEMBER 30, 2022 - OCTOBER 3, 2022 | GAYLORD NATIONAL HARBOR | WASHINGTON, DC

The HFSA Annual Scientific Meeting 2022 brings the best of heart failure science, research and practical management opportunities along with providing a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy



HFSA 2022: Overview

HFSA 2022 by Numbers

400+

Abstracts

350+

e-Posters

50+

Broadcasted Sessions


40+

Satellite Symposia & Scientific Sessions


15+

Oral Posters

Sessions (by Indications)



Key Focus during HFSA 2022



Strong emphasis anticipated on **heart failure management**, with focus on SGLT2i, cell therapy, GDMT, LVADs, etc.


Extensive focus on **cardiomyopathy**, comprising of sessions regarding cardiac myosin inhibitors, siRNA therapies and gene therapies

Multiple sessions on heart transplant with emphasis on clinical management of cardiac complications as well as infections would be highlighted

HFSA 2022: Multitude Sessions Types

HFSA 2022 Conference (by Session Type)

Total Number of Sessions: 91 [★]



Key Focus Sessions



Majority of presentations are anticipated to be a part of the **Scientific Sessions** in HFSA 2022 congress

- Key focus areas include new HF guidelines, CM management, cardio-oncology, novel device-based therapies, obesity and nutrition management in HF



Plenary Session consists of several company-sponsored sessions (pharma and medical device companies) in the congress

- Major emphasis is anticipated to be laid on SGLT2i drugs including Dapagliflozin and Empagliflozin. Also, likely presentations on Sacubitril/Valsartan and Istaroxime



At the HFSA 2022, **Industry Expert Theater** and **Contemporary Forum** are sponsored by pharma, diagnostic and medical device companies


- Likely presentations and discussions on SGLT2i, siRNA, 2022 HF guideline updates, management of worsening HFrEF, ATTR-CM, and expert perspective on the burden of symptomatic chronic HFrEF

★ Note: Sessions having no categorization have not been considered. Plenary sessions also include "late breaking clinical trials", apart from "late breaking session II"

HFSA 2022: Major CVD players and SoV



CVD players' share of voice (SoV) *



What to Expect at HFSA 2022?*

- Compared to ESC congresses, HFSA ASM 2022 seems to be more focused on **cardiomyopathy** and **cardiac amyloidosis**, fewer sessions targeting HF, particularly **HFpEF**
- Pfizer** is anticipated to present multiple sessions on **Tafamidis**
- Cytokinetics** is expected to present efficacy and safety results of **Aficamten** for obstructive HCM through an oral poster. The company is also expected to present various sessions targeting HFpEF
- BMS** and **Merck & Co.** will be focusing on HCM and HF (HFpEF) indications, respectively
- AstraZeneca** and **BI/Lilly** is expected to focus more on SGLT2 inhibitor. Also, BI/Lilly will be presenting latest data on **JARDIANCE**

* Note: Analysis has been done based on the prominent sessions backed by the key pharma companies

HFSA 2022: Key Data Presentations (1/2)

While Rocket Pharma and BioCardia will show promising clinical results for RP-A501 (gene therapy) and CardiAMP (autologous cell therapy), respectively, Windtree is anticipated to show results of Istaroxime for pre-cardiogenic shock



Drug	Indication
------	------------

Onpattro (Patisiran)	ATTR-CM
----------------------	---------



Primary results and exploratory analysis from **APOLLO-B: A Phase 3 Study Of Patisiran In Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy**



Drug	Indication
------	------------

Aficamten	Obstructive HCM
-----------	-----------------



Efficacy And Safety Of **Aficamten** In Patients With Symptomatic **Obstructive HCM**: Interim Results From The Randomized Evaluation Of Dosing With Ck-3773274 In HCM Open Label Extension Study



Drug	Indication
------	------------

Sotagliflozin	Heart Failure
---------------	---------------



Sotagliflozin, A **Dual SGLT1 And SGLT2 Inhibitor**, Reduces First And Subsequent **Heart Failure**-related Events In Patients Admitted For Worsening Heart Failure



Drug	Indication
------	------------

RP-A501	Paediatric HCM
---------	----------------



Safety Profile Of The First **Pediatric Cardiomyopathy Gene Therapy** Trial: **RP-A501** (AAV9:LAMP2B) For Danon Disease



Drug	Indication
------	------------

CardiAMP Cell Therapy	CardiAMP Cell Therapy
-----------------------	-----------------------



Autologous Cell Therapy For **HFrEF**: Efficacy Outcomes At Two Years For The Roll-in Cohort Of A Phase III Pivotal Trial



Drug	Indication
------	------------

Istaroxime	Pre-Cardiogenic Shock
------------	-----------------------



The Effects Of **Istaroxime** In Patients With **Pre-cardiogenic Shock** Due To Acute Heart Failure - **Dose Response**


HFSA 2022: Key Data Presentations (2/2)

Although Bi/Lilly and AstraZeneca are expected to provide clinical data regarding their established SGLT2 inhibitors for heart failure, companies like Cytokinetics and Alnylam are anticipated to lead in the cardiomyopathy therapy landscape



Drug	Indication
------	------------

Empagliflozin Acute Heart Failure




Effect Of **Empagliflozin** On Clinical Events In Patients Hospitalized For **Acute Heart Failure**: Results From **EMPULSE**




Drug	Indication
------	------------

Dapagliflozin HFimpEF




Dapagliflozin In **Heart Failure** With Improved Ejection Fraction (**HFimpEF**)



Drug	Indication
------	------------

Dapagliflozin HFpEF, HFrEF




Blood Pressure, **Dapagliflozin**, And Cardiovascular Outcomes In **Heart Failure** With Preserved And Mildly Reduced Ejection Fraction: **DELIVER**



Drug	Indication
------	------------

Sacubitril/Valsartan HFrEF




Effect Of **Sacubitril/valsartan** On Mitral Regurgitation In **Heart Failure** With Reduced Ejection Fraction. The **PROVE-HF** Study



Drug	Indication
------	------------

Aficamten Obstructive HCM




Improvement In KCCQ Scores In Patients With **Obstructive Hypertrophic Cardiomyopathy** Treated With **Aficamten** In The **REDWOOD-HCM OLE** Study



Drug	Indication
------	------------

AMVUTTRA (Vutrisiran) ATTR-CM



A New Treatment Option: Discover **AMVUTTRA (Vutrisiran)**

HFSA 2022: Key Themes



Heart Failure

- ▶ **Satellite symposia** by key players like **Merck, AZ, BI & Lilly** on treatment paradigm
- ▶ BI & Lilly to showcase review and latest data from Jardiance in an “**Industry Expert Theater**”
- ▶ **Cytokinetics** depicting burden and management of **HFrEF via a Satellite symposia and “Industry Expert Theater”**
- ▶ **Lexicon** to present an ePoster on effect on **Sotagliflozin** in pts admitted for worsening HF
- ▶ **BioCardia** to present data of autologous cell therapy in **Ph3 pivotal trial in HFrEF**
- ▶ LBA sessions on **DELIVER, EMPULSE and PROVE-HF trials**



Cardiomyopathy

- ▶ **BMS** to host Satellite symposia and contemporary forum on **HCM**
- ▶ Alnylam to host an “Industry Expert Theater” on **Amvuttra** (targets TTR mRNA), approved for hereditary ATTR amyloidosis in adults
 - Also, to present interim results for **Aficamten** in **HCM OLE study** including an LBA session
 - Primary results and exploratory analyses from **Apollo-B**, Ph3 study of **Patisiran** in ATTR Amyloidosis with cardiomyopathy
- ▶ **Pfizer** to present data showing **Tafamidis** is effective in ATTR Amyloidosis across Columbia stages



Guidelines/Protocols

- ▶ Contemporary forum to be held by **Merck** on HFrEF treatment and select updates from the **2022 HF Guideline**
- ▶ Scientific session on **new guidelines and evolving clinical practice in HFrEF**
- ▶ Key posters on:
 - Impact of Remote Patient Monitoring/Telehealth and **GDT Protocols** on HF management
 - Underutilization of **Guideline-directed genetic testing in Cardiomyopathies: A missed opportunity**

Interested in collaborating for
conference coverage?

Please contact us at
*EvalueteamConferences@evaluate
serve.com*

Thank You

